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Abstract
Background: The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast
cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported
that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most
studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not
with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce
attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or
presence of hormonal receptors).
Methods: In this case-control study, we report the NSAID – breast cancer relationship in 1736 breast cancer cases
and 1895 healthy controls; results are reported stratifying by the women’s characteristics (i.e.: menopausal status or
body mass index category) and by tumor characteristics.
Results: In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76;
95 % Confidence Interval [CI]: 0.64–0.89), and similar results were found for acetic acid derivatives, propionic acid
derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal
women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative
breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in
advanced clinical stage and triple negative cancers.
Conclusion: Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to
be restricted to hormone + or HER2+ cancers.
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Background
The cyclooxygenase-prostaglandin inflammation pathway
has been shown to play a relevant role in carcinogenesis,
mainly via inhibition of the cyclooxigenase-2 (COX-2) iso-
form [1]. Experimental studies have demonstrated that
COX-2 blockade inhibits breast tumor formation in mice,
while its overexpression has the opposite effect [2]. There-
fore, consumption of non-steroidal anti-inflammatory
drugs (NSAIDs) is expected to be protective for cancer
development.
Regarding breast cancer, results from epidemiological
studies are inconsistent: cohort studies have reported
very modest protective effects or no effect at all [3–5],
while case-control studies have usually reported moder-
ate protective effects [6–8]. Several meta-analyses have
been conducted; combination of results is, however,
complex because of differences in reporting of timing
and dosing of NSAIDs in the studies. The most recent
meta-analysis reported a 20 % protective effect of
NSAID especially aspirin and COX-2 inhibitors against
breast cancer, which seems to be restricted to estrogen
receptors + (ER+) or progesterone receptors + (PR+) tu-
mors [9].
The number of epidemiological studies reporting re-
sults about the COX-2 inhibitors’ effect on breast cancer
or about NSAIDs’ effect on different types of breast can-
cer (i.e.: ER+, PR+, Human epidermal growth factor re-
ceptor [HER2] +, triple negative) is still small and
further studies are needed in order to clarify the specific
effect of NSAID groups on different types of breast can-
cer [8, 10–12]. In order to further investigate this issue,
we report the results from a large case-control study
performed in Spain.
Methods
Study design and population
The Multi Case-control (MCC-Spain) study is a
population-based case-control study of common tumors
in Spain and has been described elsewhere [13]. It has
been carried out in 12 Spanish provinces. The recruit-
ment included incident cases of colorectal, breast, stom-
ach and prostate cancer or chronic lymphocytic
leukemia diagnosed between September 1st, 2008 and
December 31st, 2013, aged between 20 and 85 years old,
and resident within the influence area of the hospital at
least 6 months prior to recruitment. Cases were identified
through active search that included periodical visits to the
collaborating hospital departments (i.e. gynecology, oncol-
ogy, general surgery, radiotherapy, and pathology depart-
ments), but only histologically confirmed incident cases of
breast cancer (C50, D05.1, D05.7) with no prior history of
the disease were included in this study. Ten out of 12
provinces recruited breast cancer cases and controls. Con-
trols were selected from the general population according
to age and sex distribution of the cases included in the
study. In this paper, 1736 cases of breast cancer (ICD-10:
C50, D05) in women and 1909 frequency-matched con-
trols were considered.
Response rates were 71 % for breast cancer and 72 %
for controls, with no differences in the main socio-
demographic variables among those who participated and
those who refused to participate. The Ethics Committees
of participating hospitals approved the study protocols,
and participants provided written informed consent at the
time of enrollment.
Data collection
Participants were interviewed face-to-face by trained in-
terviewers with a comprehensive epidemiological ques-
tionnaire that assessed socio-demographic information,
personal and family history of cancer, anthropometric
data, smoking habits, occupation, physical activity, water
consumption, reproductive and medical history and
medication/drugs use, family history, sun exposure, sleep
habits, use of hygiene products and cosmetics, signs and
symptoms. Diet was assessed with the use of a validated
semi-quantitative Spanish Food Frequency Question-
naire (FFQ), which was modified to include regional
products. The FFQ included 140 food items, and
assessed usual dietary intake during the previous year.
Participant’s weight was recorded by self-report, as es-
timated one year before diagnosis for cases and for con-
trols. Body mass index (BMI) was estimated from self-
reported weight and height 1 year before the diagnosis
for cases and 1 year prior to the interview for controls.
Similar estimates provided total energy consumption.
Physical activity was recorded for all jobs and also recre-
ational physical exercise.
Detailed information was obtained on past medical
conditions and the corresponding medications used. Par-
ticipants were asked about past medical history of dia-
betes mellitus, high blood pressure, high levels of
cholesterol and triglycerides, heart attack, embolism,
other cardiovascular diseases, degenerative osteoarthritis,
arthritis, migraine or cephalalgia, gout, ulcerative colitis,
Crohn’s disease, renal calculus (nephrolithiasis or cysto-
lithiasis), chronic obstructive pulmonary disease, asthma,
bronchitis, irritable bowel syndrome, anemia, diverticu-
litis, celiac disease and cancer. The age at onset, the
dates of diagnosis or occurrence and the type of treat-
ment received for each condition was also registered.
Drug use assessment
Drug use was recorded by indication. For each drug, the
brand name, dose and duration of exposure were recorded
to identify patients with regular drug consumption
(“no and occasionally” versus “yes”) and the duration
of consumption. The drugs were coded following the
Dierssen-Sotos et al. BMC Cancer  (2016) 16:660 Page 2 of 11
Anatomical Therapeutic Chemical Classification Sys-
tem (ATC codes) to define groups with similar mecha-
nisms of action [14]. To be sure that participants
report all drugs, a general question about the use of
NSAIDs was included in order to add information that
was not provided before.
All drugs indicated for the treatment of inflammatory
diseases were considered. The main ATC code included
in the present analysis are codes B01AC06 and
N02BA01 (Aspirin) and code M01 (Antiinflammatory
and antirheumatic drugs). Data were also analyzed for
subgroups with codes M01AA (Butilpirazolidins),
M01AB (acetic acid derivatives; for instance, diclofenac,
ketorolac), M01AC (Oxicams), M01AE (propionic acid
derivatives; for instance ibuprofen, naproxen), M01AH
(Coxibs; for instance, celecoxib), M01AX (other
NSAIDs) and their combinations. Finally, as cox2 inhib-
ition has been suggested as the putative mechanisms for
NSAID protective effect on breast cancer, we performed
a subgroup analysis according to level of COX-
selectivity. In this way, NSAIDs were grouped in cox1-
selective/cox2-selective according to their log [IC80 ratio
(WHMA COX-2/COX-1)] [15]. NSAIDs with negative
log (IC80 ratio) were considered cox2-selective (for in-
stance, meloxicam, diclofenac, sulindac, piroxicam,
niflumic acid), while NSAIDs with positive log (IC80 ra-
tio) were considered cox1-selective (for instance: ibu-
profen, naproxen, indomethacin, ketoprofen, ketorolac).
As the putative protective mechanism of aspirin is not
via cox-2 inhibition, we retained aspirin as an independ-
ent group.
Statistical methods
Unconditional logistic regression was used to assess the
association between treatment of NSAID use and breast
cancer, adjusting for age, recruitment area, education
level, tobacco smoking history, BMI, family history of
breast cancer, number of deliveries, age at first delivery,
menarche age, and menopausal status. Stratified models
were developed according to menopausal status and
BMI [<25/≥25 kg/m2]. The association between tumor
characteristics (clinical stage, ductal/non-ductal cancer,
hormone receptors, HER2 receptors and triple negative
breast cancer) and NSAID consumption was studied
using multinomial logistic regression. Results are re-
ported as odds ratios (OR) with 95 % confidence inter-
vals (CI). All reported p-values are two-tailed. Statistical
analysis was carried out using the package Stata 12/SE
(StataCorp, College Station, Tx, US).
Results
A description of the 1736 cases and 1909 controls in-
cluded in this study is provided in Table 1. Significant
differences are observed between cases and controls for
several well known risk factors for breast cancer, includ-
ing family history of breast cancer, age at menarche,
and tobacco smoking. Clinical-pathological characteris-
tics of the breast cancers are reported in Table 2; ductal
cancer accounts for 85 % of cases; two out of three
breast cancers were diagnosed at stage I or II; more
than 70 % of cancers were estrogen receptors +, 14 %
were HER2 receptors + and only 6 % were triple nega-
tive breast cancers. Results on NSAID consumption –
breast cancer association are reported here for con-
sumption of any NSAID, aspirin, acetic acid derivatives,
propionic acid derivatives, COX-2 inhibitors (COXIBs),
and other NSAIDs. We do not report results on butil-
pirazolidins because of the small number of women ex-
posed to this group.
NSAID consumption and breast cancer according to
women’s characteristics
Results on the relationship between NSAID consumption
and breast cancer overall and by menopausal status and
BMI, according to women’s characteristics are reported in
Tables 3 and 4 for duration of use, and Additional file 1:
Table S1 according to COX2/COX1 selectivity. NSAIDs
as a global group protected against breast cancer (OR =
0.76; 95 % CI: 0.64–0.89); a protective effect was also
found for acetic acid derivatives, propionic acid deriva-
tives and COXIBs, but not for aspirin, although COXIB
results were based on small numbers of exposed cases
and controls, hampering further analysis of their effect
in specific subgroups of women. When stratifying for
menopausal status, all NSAIDs, acetic acid derivatives,
propionic acid derivatives and COXIBs showed a pro-
tective effect in postmenopausal women; ORs in post-
menopausal women were similar or slightly lower to
those in premenopausal women. P values for NSAID –
menopausal interaction status were higher than 0.10 (p
values not shown). The protective effect of any NSAID
was independent of BMI; however, the effect varied in
subgroups: acetic acid derivatives were protective in
women with BMI < 25 kg/m2 (OR = 0.54; 95 % CI:
0.31–0.93) but not in overweight or obese women,
while propionic acid derivatives (OR = 0.78; 95 % CI:
0.61–1.00) protected only in the latter group; p values
for BMI – NSAID interaction were non-significant.
Table 4 reports the results according to the duration of
NSAID consumption (never/less than 5 years/more
than 5 years). It shows that most of the results described
in the paragraph above had consistent dose-effect relation-
ship: the longer the consumption, the lower the odds ratio.
Additional file 1: Table S1 shows a greater protective effect
of COX-2 both globally (OR = 0.66; 95 % CI: 0.48–0.90 for
COX-2 vs OR = 0.81; 95 % CI: 0.67–0.98) for COX-1 se-
lectivity) and in postmenopausal women and in women
with BMI <25 kg/m2.
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NSAID consumption and breast cancer according to
tumor characteristics
Results for subgroups of breast cancer are reported in
Tables 5 and 6 (for duration of use) and Additional file
2: Table S2 (according to COX2/COX1 selectivity). The
protective effect of any NSAID seemed similar in early
or late clinical stages (OR = 0.80; 95 % CI: 0.66–0.97 in
stages 1–2; OR = 0.74; 95 % CI: 0.51–1.06 in stages 3–4),
but no specific NSAID group reached statistically signifi-
cant effect. Consumption of any NSAID, acetic acid de-
rivatives and propionic acid derivatives was protective
for ductal cancer (OR for any NSAID = 0.70; 95 % CI:
Table 1 Main characteristics of cases and controls from the study population
Variable Category Cases Controls p
Age, mean ± sd 56.4 ± 12.6 59.0 ± 13.2 <0.001
Geographical area, n (%) Asturias 70 (4.0) 121 (6.4)
Barcelona 292 (16.8) 380 (20.1)
Cantabria 141 (8.1) 188 (9.9)
Gerona 47 (2.7) 57 (3.0)
Guipuzcoa 226 (13.0) 255 (13.5)
Huelva 105 (6.1) 79 (4.2)
Leon 227 (13.1) 202 (10.7)
Madrid 341 (19.6) 365 (19.3)
Navarra 226 (13.0) 181 (9.6)
Valencia 61 (3.5) 67 (3.5) <0.001
Family history of breast cancer, n (%) No 1288 (75.0) 1628 (85.7)
First-degree relative 256 (14.9) 166 (8.7)
Second-degree relative 174 (10.1) 106 (5.8) <0.001
Educational level, n (%) Less than primary school 268 (15.4) 327 (17.3)
Primary school 565 (32.6) 581 (30.7)
Secondary school 573 (33.0) 585 (30.9)
University 330 (19.0) 402 (21.2) 0.10
Tobacco smoking, n (%) Never smoker 972 (56.0) 1141 (60.2)
Former smoker 450 (25.9) 397 (21.0)
Current smoker 314 (18.1) 357 (18.8) 0.002
Body Mass Index (kg/m2), n (%) <18.5 30 (1.7) 43 (2.3)
18.5–24.9 789 (45.5) 899 (47.4)
25.0–29.9 590 (34.0) 601 (31.7)
≥30 327 (18.8) 352 (18.6) 0.31
Energy intake (kcal/day), mean ± sd 1861 ± 644 1754 ± 566 <0.001
Ethanol intake (g/day), mean ± sd 6.2 ± 11.5 5.3 ± 9.5 0.01
Red meat intake (g/day), mean ± sd 26.9 ± 20.2 25.2 ± 19.9 0.01
Fruit intake (g/day), mean ± sd 363 ± 239 365 ± 222 0.87
Vegetable intake (g/day), mean ± sd 196 ± 133 198 ± 119 0.60
Dairy intake (g/day), mean ± sd 321.1 ± 177.1 328.7 ± 176.7 0.24
Number of deliveries, mean ± sd 1.9 ± 1.5 2.0 ± 1.6 0.03
Menopausal status, n (%) Premenopausal 702 (40.4) 628 (33.1)
Postmenopausal 1034 (59.6) 1267 (66.9) <0.001
Age at first delivery, mean ± sd 26.5 ± 5.0 26.5 ± 4.7 0.82
Age at menarche, mean ± sd 12.8 ± 1.5 12.9 ± 1.5 0.02
Age at menopause, mean ± sd 48.8 ± 5.4 48.5 ± 5.3 0.18
Previous use of hormonal contraceptives, n (%) 789 (45.5) 868 (45.8) 0.83
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0.58–0.84) but not for non-ductal cancer, although the p
value for heterogeneity was non-significant for NSAID
as a group or for any specific subgroup. All NSAID con-
sumption was protective for hormone receptor + cancer
(i.e.: ER+ or PR+) (OR = 0.72; 95 % CI: 0.60–0.88) and
HER2+ cancers (OR = 0.63; 95 %: 0.45–0.88). Propionic
acid derivatives also showed this protective effect in hor-
mone + or HER2+ cancers, while acetic acid derivatives
showed a non-statistically significant effect (OR = 0.76;
95 % CI: 0.54–1.08 in hormone receptor + cancers and
OR = 0.67; 95 % CI: 0.36–1.24 in HER2 receptor + can-
cers). Neither consumption of NSAID in general nor any
specific NSAID subgroup showed a protective effect in
triple negative breast cancers.
When studying the effect of length of consumption
(Table 6), most associations reported above were at least
as strong in patients with more than 5 years of consump-
tion as in patients with less than 5 years.
Finally, regarding the COX-selectivity of the NSAID
(Additional file 2: Table S2), the COX-2 selectivity showed
an inverse association with breast cancer (i.e. OR < 1), ex-
cept in advanced clinical stage and triple negative cancers.
Discussion
In this large case-control study, NSAID use was associated
with a 24 % reduction in breast cancer risk. An inverse
association were observed specifically for acetic acid de-
rivative and propionic acid derivative use, but not for as-
pirin consumption. There is a trend towards a stronger
protective effect of NSAID in postmenopausal women,
ductal cancer, and hormone receptor or HER2 receptor
positive tumors. This protective effect was less pro-
nounced in premenopausal women, non-ductal cancer, or
triple negative cancer, although the small number of cases
with triple negative cancer makes it difficult to reach de-
finitive conclusions.
Regarding NSAID effect overall, our results are coher-
ent with those reported in 10 out of 16 case-control
studies [6–8, 16–22], while the remaining six studies did
not show any effect [23–28]. Results from 13 cohort
studies hardly support any NSAID effect on breast can-
cer risk; only four reported protective effects [3, 4, 29,
30], seven did not find any association [5, 31–35], and
three reported an increase in breast cancer risk [36–38].
Consequently, a recent meta-analysis [9] showed a sig-
nificant protective odds ratio (OR = 0.82) when combin-
ing case-control studies, but a non-significant relative
risk (RR = 0.92) in cohort studies. Most studies, however,
did not report stratified results.
Some studies have analyzed the effect of aspirin, ibu-
profen or non-aspirin NSAIDs, reporting similar results
to those presented for NSAIDs in general (i.e.: protective
effect in case-control studies; no effect in cohort studies)
[9]. Scarce attention has been paid, however, to the effect
associated with different pharmacological subgroups.
According to our results, acetic acid derivatives, propio-
nic acid derivatives and COX-2 inhibitors have a pro-
tective effect against breast cancer incidence, while
aspirin has no effect at all. The absence of a significant
effect of aspirin is puzzling since prior investigations
have noted not only preventive effects but also thera-
peutic effects of aspirin against breast cancer. In this re-
gard, aspirin consumption could be underreported in
our study due to its common over-the-counter usage; as
this possible underreporting would affect both cases and
controls in a similar way, it would eventually lead to a
bias towards the null, which would justify a negative re-
sult. This phenomenon is not to be expected in other
NSAIDs as their usual consumption is by prescription.
The public health implications of the reduction in
breast cancer risk when taking acetic acid and propionic
acid derivatives should be highlighted as these groups
account for about 80 % of NSAID consumption in the
Spanish population. A note of caution should be
remarked on aspirin results; the percentage of people
declaring aspirin consumption seems low, which could
be due to a reporting bias. Study participants were asked
to report the diseases they were suffering from and the
drugs they had been taking for treating them and we
have also asked whether they were taking any other
Table 2 Clinical and pathological characteristics of breast cancers
Classification N (%)
Pathology
Ductal 1289 (74.3)
Lobular 112 (6.5)
Papilar 22 (1.3)
Coloid 20 (1.2)
Tubular 12 (0.7)
Mixed 27 (1.6)
Other 35 (2.0)
Not Available 213 (12.3)
Clinical stage
0 115 (6.6)
I 604 (34.8)
II 495 (28.5)
III 182 (10.5)
IV 22 (1.3)
Not Available 196 (11.3)
Inmunohistochemistry
Progesterone 992 (62.5)
Estrogens 1147 (72.2)
HER2 227 (14.3)
Triple negative 92 (5.8)
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NSAID not reported before. It is possible that some
people might not consider aspirin to be a drug, so failing
to declare its usage.
Most studies did not analyze NSAID effect on several
types of breast cancer. According to our results, the in-
verse association of NSAID with breast cancer is more
pronounced in postmenopausal cancers, ductal cancer,
and hormone receptor or HER2 receptor positive tumors.
This effect increases in women treated with COX-2 in-
hibitors, especially in early clinical stage, postmeno-
pausal cancers and receptor positive tumors. The
putative pathway for the NSAID protective effect is via
COX inhibition. High levels of prostaglandins, derived
from the activation of the COX/prostaglandin pathway,
contribute to carcinogenesis in various ways (increase in
mitogenesis, mutagenesis, angiogenesis, metastasis forma-
tion, inhibition of apoptosis, and immunosuppression)
[38–40]. Constitutive expression of the COX-2 gene and
sustained biosynthesis of PGE2 seem to be associated with
the initiation and promotion of breast carcinogenesis [41].
In a prospective study, COX-2 expression in biopsy speci-
mens from women with atypical breast hyperplasia was a
significant predictor of breast cancer risk [42]; COX-2
overexpression, therefore, seems to constitute an early
event in breast carcinogenesis, which makes COX-2 a
potential cancer biomarker and a key target for breast
cancer prevention [43]. Unfortunately, cardiovascular tox-
icity attributed to COX-2 inhibitors has partially decreased
Table 3 Relationship between NSAID consumption and breast cancer according to women’s characteristics
Population NSAID Unexposed controls/cases (n) Exposed controls/Cases (n) OR (95 % CI) p
All women NSAID (all) 1170/1111 739/625 0.76 (0.64–0.89) 0.001
Aspirin 1807/1653 102/83 0.91 (0.64–1.29) 0.60
Acetic acid derivatives 1753/1620 156/116 0.75 (0.55–1.01) 0.06
Propionic acid derivatives 1350/1232 559/504 0.82 (0.69–0.98) 0.03
cox2 inhibitors 1891/1731 18/5 0.28 (0.09–0.88) 0.03
NSAID others 1861/1697 48/39 1.13 (0.67–1.89) 0.65
Premenopausal NSAID (all) 361/415 267/287 0.80 (0.60–1.07) 0.14
Aspirin 613/689 15/13 0.60 (0.25–1.47) 0.27
Acetic acid derivatives 600/664 28/38 0.75 (0.42–1.36) 0.35
Propionic acid derivatives 392/451 236/251 0.84 (0.62–1.13) 0.24
cox2 inhibitors 626/701 2/1 - -
NSAID others 618/693 10/9 1.26 (0.41–3.9) 0.69
Postmenopausal NSAID (all) 804/696 462/338 0.69 (0.56–0.86) <0.001
Aspirin 1180/964 86/70 0.99 (0.68–1.46) 0.98
Acetic acid derivatives 1142/956 124/78 0.72 (0.50–1.03) 0.07
Propionic acid derivatives 953/781 313/253 0.78 (0.62–0.98) 0.03
cox2 inhibitors 1250/1030 16/4 - -
NSAID others 1228/1004 38/30 1.05 (0.58–1.90) 0.86
BMI <25 NSAID (all) 578/537 364/282 0.73 (0.57–0.94) 0.02
Aspirin 901/794 41/25 0.74 (0.40–1.35) 0.32
Acetic acid derivatives 883/783 59/36 0.54 (0.31–0.93) 0.03
Propionic acid derivatives 656/575 286/244 0.86 (0.66–1.13) 0.27
cox2 inhibitors 932/816 10/3 - -
NSAID others 919/806 23/13 0.98 (0.42–2.31) 0.97
BMI >25 NSAID (all) 592/574 375/343 0.76 (0.60–0.95) 0.02
Aspirin 906/859 61/58 1.01 (0.65–1.56) 0.96
Acetic acid derivatives 870/837 97/80 0.81 (0.56–1.18) 0.27
Propionic acid derivatives 694/657 273/260 0.78 (0.61–1.00) 0.05
cox2 inhibitors 959/915 8/2 - -
NSAID others 942/891 25/26 1.24 (0.64–2.41) 0.52
OR Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI family history of breast cancer, number of deliveries, age at first
delivery, menarche age, and menopausal status. CI confidence interval
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their usefulness, whatever their effect on breast cancer
might be.
On the other hand, COX inhibition would reduce aro-
matase activity [44]. Peripheral aromatization of fatty acids
is known to be largely responsible for estrogen production
in postmenopausal women –in whom adipose tissue rep-
resents an important local source of estrogen-; therefore,
regulation of aromatase synthesis in the breast could be
particularly important in postmenopausal breast cancer
[45]. Reducing aromatase activity via COX inhibition could
also explain, at least partially, the decrease in breast cancer
incidence linked to NSAID use [8], since COX inhibition
would reduce estrogen concentration in the breast,
restricting the growth of estrogen-dependent tumors.
This study has several limitations. First, NSAID con-
sumption was self-reported, which could introduce a re-
call bias. For a recall bias to be responsible for the
protective effects reported here, the bias would have to
be differential in cases and controls, with controls re-
membering their previous NSAID consumption better;
this seems counterintuitive as one would expect cases to
be more motivated for remembering their previous ex-
posures. In addition, if cases are less prone to report
their NSAID usage, the same bias would be expected in
all NSAID groups and in each stratum analyzed; how-
ever, our results were different according to the type of
NSAID, which seems to contradict such a bias. More-
over, in order to minimize a differential recall bias, inter-
viewers were blinded to the case-control status of the
participants. Second, although our intention was to rec-
ord data on aspirin dosage, most patients did not pro-
vide sufficiently detailed data on dosages of aspirin or
other NSAID use. This fact prevents us from analyzing
the dose-effect relationship. Third, we have adjusted for
the usual confounders but residual confounding cannot
be ruled out. Finally, any case-control study could be
Table 4 Relationship between length of non-steroideal anti-inflammatory drug consumption and breast cancer, according to
women’s characteristics
Population NSAID No consumption Consumption ≤5y Consumption >5y
Controls/cases (n) Controls/cases (n) OR (95 % CI) Controls/cases (n) OR (95 % CI)
All women NSAID (all) 1171/1111 484/445 0.81 (0.67–0.98) 255/180 0.64 (0.50–0.83)
Aspirin 1808/1653 79/70 0.99 (0.67–1.46) 23/13 0.65 (0.31–1.38)
Acetic acid derivatives 1754/1620 113/86 0.75 (0.53–1.06) 43/30 0.75 (0.42–1.32)
Propionic acid derivatives 1351/1232 380/364 0.86 (0.71–1.06) 179/140 0.73 (0.55–0.97)
NSAID others 1862/1697 33/35 1.47 (0.83–2.60) 15/4 -
Premenopausal NSAID (all) 361/415 162/187 0.82 (0.59–1.13) 105/100 0.78 (0.52–1.17)
Aspirin 613/689 12/12 0.72 (0.27–1.95) 3/1 -
Acetic acid derivatives 600/664 21/27 0.68 (0.35–1.34) 7/11 1.02 (0.31–3.32)
Propionic acid derivatives 392/461 146/167 0.85 (0.61–1.19) 90/84 0.81 (0.52–1.25)
NSAID others 618/693 6/8 2.38 (0.63–9.00) 4/1 -
Postmenopausal NSAID (all) 805/696 312/258 0.77 (0.61–0.98) 150/80 0.53 (0.38–0.75)
Aspirin 1181/964 66/58 1.08 (0.70–1.66) 20/12 0.74 (0.33–1.65)
Acetic acid derivatives 1143/956 88/59 0.76 (0.50–1.15) 36/19 0.61 (0.31–1.20)
Propionic acid derivatives 954/781 224/197 0.84 (0.64–1.09) 89/56 0.64 (0.43–0.95)
NSAID others 1229/1004 27/27 1.27 (0.66–2.42) 11/3 -
BMI <25 NSAID (all) 578/537 233/183 0.78 (0.58–1.04) 131/99 0.65 (0.45–0.94)
Aspirin 901/794 32/22 0.84 (0.43–1.63) 9/3 -
Acetic acid derivatives 883/783 44/22 0.40 (0.20–0.77) 15/14 1.16 (0.42–3.15)
Propionic acid derivatives 656/575 191/163 0.89 (0.66–1.21) 95/81 0.80 (0.52–1.22)
NSAID others 919/806 14/11 1.51 (0.56–4.06) 9/2 -
BMI >25 NSAID (all) 593/574 251/262 0.84 (0.65–1.08) 124/81 0.61 (0.43–0.86)
Aspirin 907/859 47/48 1.10 (0.68–1.80) 14/10 0.74 (0.30–1.82)
Acetic acid derivatives 871/837 69/64 0.94 (0.61–1.44) 28/16 0.54 (0.27–1.10)
Propionic acid derivatives 695/657 189/201 0.85 (0.64–1.12) 84/59 0.64 (0.43–0.95)
NSAID others 943/891 19/24 1.44 (0.71–2.95) 6/2 -
OR Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI family history of breast cancer, number of deliveries, age at first
delivery, menarche age, and menopausal status. CI confidence interval
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Table 5 Relationship between consumption of non-steroideal anti-inflammatory drugs and breast cancer, according to tumor characteristics
Variable Category NSAID Unexposed
controls/cases (n)
Exposed
controls/cases (n)
OR (95 % CI) P
Clinical stage 1–2 NSAID (all) 1170/696 739/404 0.80 (0.66–0.97 0.02
Aspirin 1807/1047 102/52 0.93 (0.63–1.38) 0.72
Acetic acid derivatives 1753/1025 156/74 0.75 (0.54–1.06) 0.11
Propionic acid derivatives 1350/770 559/329 0.90 (0.74–1.11) 0.33
cox2 inhibitors 1891/1095 18/4 - -
NSAID others 1861/1072 48/27 1.07 (0.61–1.90) 0.81
3–4 NSAID (all) 1170/136 739/68 0.74 (0.51–1.06) 0.10
Aspirin 1807/192 102/12 1.31 (0.66–2.59) 0.44
Acetic acid derivatives 1753/190 156/14 0.99 (0.53–1.83) 0.97
Propionic acid derivatives 1350/147 559/57 0.84 (0.57–1.24) 0.39
cox2 inhibitors 1891/204 18/0 - -
NSAID others 1861/201 48/3 - -
Pathology Ductal cancer NSAID (all) 1170/835 739/454 0.70 (0.58–0.84) <0.001
Aspirin 1807/1225 102/64 0.97 (0.66–1.41) 0.86
Acetic acid derivatives 1753/1204 156/85 0.76 (0.55–1.06) 0.11
Propionic acid derivatives 1350/918 559/371 0.78 (0.64–0.95) 0.01
cox2 inhibitors 1891/1289 18/3 - -
NSAID others 1861/1259 48/30 1.06 (0.60–1.87) 0.85
Non-ductal cancer NSAID (all) 1170/151 739/83 0.82 (0.58–1.15) 0.25
Aspirin 1807/228 102/6 0.50 (0.21–1.19) 0.12
Acetic acid derivatives 1753/219 156/15 0.85 (0.46–1.58) 0.61
Propionic acid derivatives 1350/166 559/68 0.91 (0.63–1.31) 0.60
cox2 inhibitors 1891/234 18/0 - -
NSAID others 1861/232 48/2 - -
Inmunohistochemistry Hormone + NSAID (all) 1170/727 739/390 0.72 (0.60–0.88) <0.001
Aspirin 1807/1069 102/48 0.82 (0.55–1.24) 0.35
Acetic acid derivatives 1753/1044 156/73 0.76 (0.54–1.08) 0.12
Propionic acid derivatives 1350/805 559/312 0.80 (0.65–0.98) 0.03
cox2 inhibitors 1891/1115 18/2 - -
NSAID others 1861/1089 48/28 1.28 (0.73–2.25) 0.38
HER2+ NSAID (all) 1170/739 172/83 0.63 (0.45–0.88) 0.007
Aspirin 1807/102 244/11 0.79 (0.38–1.65) 0.53
Acetic acid derivatives 1753/238 156/17 0.67 (0.36–1.24) 0.20
Propionic acid derivatives 1350/188 559/67 0.66 (0.46–0.95) 0.03
cox2 inhibitors 1891/255 18/0 - -
NSAID others 1861/251 48/4 - -
Triple negative
breast cancer
NSAID (all) 1170/94 739/63 0.87 (0.58–1.30) 0.49
Aspirin 1807/148 102/9 1.24 (0.57–2.71) 0.59
Acetic acid derivatives 1753/147 156/10 0.86 (0.41–1.79) 0.68
Propionic acid derivatives 1350/103 559/54 0.99 (0.64–1.52) 0.95
cox2 inhibitors 1891/156 18/1 - -
NSAID others 1861/154 48/3 - -
OR Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI family history of breast cancer, number of deliveries, age at first
delivery, menarche age, and menopausal status. CI confidence interval
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affected by a selection bias. Our study is population
based, as controls have been selected from the same
residence area as cases; the small differences in case and
control educational levels suggest that the selection has
been adequately carried out. Moreover, the high re-
sponse rates obtained in this study (71 % for breast can-
cer cases and 72 % for controls, respectively) minimize
the possibility of occurrence of such bias.
Table 6 Relationship between length of non-steroideal anti-inflammatory drug consumption and breast cancer, according to tumor
characteristics
Variable Category NSAID No consumption Consumption ≤5y Consumption >5y
Controls/cases
(n)
Controls/cases
(n)
OR (95 % CI) Controls/cases
(n)
OR (95 % CI)
Clinical stage 1–2 NSAID (all) 1171/695 484/281 0.85 (0.69–1.06) 255/123 0.69 (0.52–0.92)
Aspirin 1808/1047 79/44 1.01 (0.65–1.58) 23/8 0.74 (0.31–1.73)
Acetic acid
derivatives
1754/1025 113/53 0.79 (0.53–1.17) 43/21 0.73 (0.38–1.42)
Propionic acid derivatives 1351/770 380/234 0.93 (0.73–1.17) 179/95 0.78 (0.57–1.08)
NSAID others 1862/1072 33/24 1.56 (0.82–2.95) 15/3 -
3–4 NSAID (all) 1171/136 484/54 0.85 (0.57–1.27) 255/14 0.46 (0.24–0.88)
Aspirin 1808/192 79/11 1.61 (0.78–3.34) 23/1 -
Acetic acid derivatives 1754/190 113/12 1.08 (0.54–2.17) 43/2 -
Propionic acid derivatives 1351/147 380/45 0.91 (0.59–1.40) 179/12 0.54 (0.27–1.09)
NSAID others 1862/201 33/3 - 15/0 -
Pathology Ductal cancer NSAID (all) 1171/835 484/324 0.74 (0.60–0.91) 255/130 0.60 (0.45–0.79)
Aspirin 1808/1225 79/56 1.09 (0.72–1.66) 23/8 0.60 (0.26–1.41)
Acetic acid derivatives 1754/1204 113/64 0.78 (0.53–1.14) 43/21 0.68 (0.36–1.30)
Propionic acid derivatives 1351/918 380/270 0.81 (0.65–1.02) 179/101 0.68 (0.49–0.94)
NSAID others 1862/1259 33/28 1.42 (0.77–2.67) 15/2
Non-ductal cancer NSAID (all) 1171/151 484/50 0.78 (0.53–1.15) 255/33 0.90 (0.55–1.48)
Aspirin 1808/228 79/5 0.59 (0.23–1.53) 23/1 -
Acetic acid derivatives 1754/219 113/11 0.92 (0.45–1.87) 43/4 -
Propionic acid derivatives 1351/166 380/40 0.79 (0.51–1.22) 179/28 1.15 (0.67–1.96)
NSAID others 1862/232 33/1 - 15/1 -
Inmunohisto-
chemistry
Hormone + NSAID (all) 1171/727 484/267 0.74 (0.60–0.92) 256/123 0.69 (0.52–0.92)
Aspirin 1808/1069 79/38 0.85 (0.54–1.36) 23/10 0.79 (0.36–1.75)
Acetic acid
derivatives
1754/1044 113/50 0.69 (0.46–1.04) 43/23 0.94 (0.51–1.75)
Propionic acid derivatives 1351/805 380/221 0.82 (0.65–1.04) 179/91 0.76 (0.55–1.05)
NSAID others 1862/1089 33/25 1.62 (0.87–3.01) 15/3 -
HER2 +/Hormone- NSAID (all) 1171/172 484/61 0.70 (0.48–1.01) 255/22 0.49 (0.28–0.87)
Aspirin 1808/244 79/10 0.89 (0.41–1.96) 23/1 -
Acetic acid derivatives 1754/238 113/16 1.02 (0.29–3.60) 43/1 -
Propionic acid derivatives 1351/188 380/47 0.66 (0.43–0.99) 179/20 0.61 (0.33–1.12)
NSAID others 1862/251 33/4 - 15/0 -
Triple negative
breast cancer
NSAID (all) 1171/94 484/49 0.94 (0.60–1.48) 255/14 0.60 (0.30–1.17)
Aspirin 1808/148 79/9 1.74 (0.78–3.89) 23/0 -
Acetic acid derivatives 1754/144 113/8 0.85 (0.36–2.01) 43/2 -
Propionic acid derivatives 1351/103 380/42 1.04 (0.64–1.68) 179/12 0.68 (0.32–1.43)
NSAID others 1862/154 33/2 - 15/1 -
OR odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI family history of breast cancer, number of deliveries, age at first
delivery, menarche age, and menopausal status. CI: confidence interval
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Conclusions
Summarizing, although there is increasing evidence for a
protective effect of NSAID against breast cancer risk,
our results indicate that this effect is more pronounced
in postmenopausal women and in estrogen/progester-
one + receptor or HER2+ cancers. As this effect seems
to be moderate, concerns remain about whether NSAID
may play a role in chemoprevention or just indicate a
pathway for identifying further more specific drugs that
could be used for breast cancer chemoprevention in high
risk women.
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